Lgals1 — Galectin 1 is a gene that has been implicated in neurodegenerative diseases. This page provides detailed information about its function, related proteins, pathways, and relevance to disease mechanisms.
LGALS1 (Galectin-1), also known as galectin-1 or β-galactoside-binding lectin, is a member of the galectin family of carbohydrate-binding proteins. Unlike classical lectins, galectin-1 does not have a signal peptide and is secreted through a non-classical pathway. This protein plays critical roles in immune modulation, neuronal development, and has emerged as an important regulator of neuroinflammation and neurodegenerative disease pathogenesis.
The LGALS1 gene is located on chromosome 22q13.1 and consists of four exons encoding a protein of 135 amino acids. The gene is conserved across species, with orthologs in rodents, zebrafish, and invertebrates.
LGALS1 performs diverse biological functions:
LGALS1 shows dynamic expression:
| Cell Type | Expression Level |
|---|---|
| Neurons | High (specific subtypes) |
| Astrocytes | High |
| Microglia | Moderate |
| Schwann Cells | High |
| Immune Cells | Variable |
In the nervous system, LGALS1 is upregulated during development and in response to injury.
Galectin-1 binds β-galactosides:
Galectin-1-targeting strategies:
| Model | Findings |
|---|---|
| LGALS1 Knockout Mice | Enhanced T-cell proliferation, altered immune response |
| Transgenic LGALS1 | Neuroprotection in stroke models |
| EAE Model (MS) | Reduced disease severity with galectin-1 |
The study of Lgals1 — Galectin 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Dumic J, et al. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616-635.
[2] Liu FT, et al. Galectins: structure, function and therapeutic potential. Immunol Rev. 2009;230(1):1-21.
[3] Hsu DK, et al. Galectin-3 in autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(8):831-838.
[4] Yip W, et al. Galectin-3 in neurodegenerative diseases. J Neurochem. 2021;157(4):1055-1072.
[5] St-Pierre M, et al. Galectin-1 and CNS regeneration. Glia. 2022;70(1):1-16.